Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of candida auris infections

Research output: Contribution to journal › Review › Research › peer-review

Standard

Ibrexafungerp : A novel oral triterpenoid antifungal in development for the treatment of candida auris infections. / Ghannoum, Mahmoud; Arendrup, Maiken Cavling; Chaturvedi, Vishnu P.; Lockhart, Shawn R.; McCormick, Thomas S.; Chaturvedi, Sudha; Berkow, Elizabeth L.; Juneja, Deven; Tarai, Bansidhar; Azie, Nkechi; Angulo, David; Walsh, Thomas J.

In: Antibiotics, Vol. 9, No. 9, 539, 2020, p. 1-13.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Ghannoum, M, Arendrup, MC, Chaturvedi, VP, Lockhart, SR, McCormick, TS, Chaturvedi, S, Berkow, EL, Juneja, D, Tarai, B, Azie, N, Angulo, D & Walsh, TJ 2020, 'Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of candida auris infections', Antibiotics, vol. 9, no. 9, 539, pp. 1-13. https://doi.org/10.3390/antibiotics9090539

APA

Ghannoum, M., Arendrup, M. C., Chaturvedi, V. P., Lockhart, S. R., McCormick, T. S., Chaturvedi, S., Berkow, E. L., Juneja, D., Tarai, B., Azie, N., Angulo, D., & Walsh, T. J. (2020). Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of candida auris infections. Antibiotics, 9(9), 1-13. [539]. https://doi.org/10.3390/antibiotics9090539

Vancouver

Ghannoum M, Arendrup MC, Chaturvedi VP, Lockhart SR, McCormick TS, Chaturvedi S et al. Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of candida auris infections. Antibiotics. 2020;9(9):1-13. 539. https://doi.org/10.3390/antibiotics9090539

Author

Ghannoum, Mahmoud ; Arendrup, Maiken Cavling ; Chaturvedi, Vishnu P. ; Lockhart, Shawn R. ; McCormick, Thomas S. ; Chaturvedi, Sudha ; Berkow, Elizabeth L. ; Juneja, Deven ; Tarai, Bansidhar ; Azie, Nkechi ; Angulo, David ; Walsh, Thomas J. / Ibrexafungerp : A novel oral triterpenoid antifungal in development for the treatment of candida auris infections. In: Antibiotics. 2020 ; Vol. 9, No. 9. pp. 1-13.

Bibtex

@article{e42fdbd99852487ab664899c9d2e5b8e,
title = "Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of candida auris infections",
abstract = "Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only available intravenously and are associated with increasingly higher rates of resistance by C. auris. Thus, a need exists for novel treatments that demonstrate potent activity against C. auris. Ibrexafungerp is a first-in-class triterpenoid antifungal agent. Similar to echinocandins, ibrexafungerp inhibits (1→3)-β-D-glucan synthase, a key component of the fungal cell wall, resulting in fungicidal activity against Candida spp. Ibrexafungerp demonstrates broad in vitro activity against various Candida spp. including C. auris and C. auris isolates with fks mutations. Minimum inhibitory concentration (MIC50 and MIC90) values in >400 C. auris isolates were 0.5 µg/mL and 1.0 µg/mL, respectively. Clinical results were reported for two patients with invasive candidiasis or candidemia due to C. auris treated during the CARES (Candidiasis Caused by Candida Auris) trial, an ongoing open-label study. These patients experienced a complete response after treatment with ibrexafungerp. Thus, ibrexafungerp represents a promising new antifungal agent for treating C. auris infections.",
keywords = "Antifungal, Candida auris, Ibrexafungerp, Resistance",
author = "Mahmoud Ghannoum and Arendrup, {Maiken Cavling} and Chaturvedi, {Vishnu P.} and Lockhart, {Shawn R.} and McCormick, {Thomas S.} and Sudha Chaturvedi and Berkow, {Elizabeth L.} and Deven Juneja and Bansidhar Tarai and Nkechi Azie and David Angulo and Walsh, {Thomas J.}",
year = "2020",
doi = "10.3390/antibiotics9090539",
language = "English",
volume = "9",
pages = "1--13",
journal = "Antibiotics",
issn = "2079-6382",
publisher = "M D P I AG",
number = "9",

}

RIS

TY - JOUR

T1 - Ibrexafungerp

T2 - A novel oral triterpenoid antifungal in development for the treatment of candida auris infections

AU - Ghannoum, Mahmoud

AU - Arendrup, Maiken Cavling

AU - Chaturvedi, Vishnu P.

AU - Lockhart, Shawn R.

AU - McCormick, Thomas S.

AU - Chaturvedi, Sudha

AU - Berkow, Elizabeth L.

AU - Juneja, Deven

AU - Tarai, Bansidhar

AU - Azie, Nkechi

AU - Angulo, David

AU - Walsh, Thomas J.

PY - 2020

Y1 - 2020

N2 - Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only available intravenously and are associated with increasingly higher rates of resistance by C. auris. Thus, a need exists for novel treatments that demonstrate potent activity against C. auris. Ibrexafungerp is a first-in-class triterpenoid antifungal agent. Similar to echinocandins, ibrexafungerp inhibits (1→3)-β-D-glucan synthase, a key component of the fungal cell wall, resulting in fungicidal activity against Candida spp. Ibrexafungerp demonstrates broad in vitro activity against various Candida spp. including C. auris and C. auris isolates with fks mutations. Minimum inhibitory concentration (MIC50 and MIC90) values in >400 C. auris isolates were 0.5 µg/mL and 1.0 µg/mL, respectively. Clinical results were reported for two patients with invasive candidiasis or candidemia due to C. auris treated during the CARES (Candidiasis Caused by Candida Auris) trial, an ongoing open-label study. These patients experienced a complete response after treatment with ibrexafungerp. Thus, ibrexafungerp represents a promising new antifungal agent for treating C. auris infections.

AB - Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only available intravenously and are associated with increasingly higher rates of resistance by C. auris. Thus, a need exists for novel treatments that demonstrate potent activity against C. auris. Ibrexafungerp is a first-in-class triterpenoid antifungal agent. Similar to echinocandins, ibrexafungerp inhibits (1→3)-β-D-glucan synthase, a key component of the fungal cell wall, resulting in fungicidal activity against Candida spp. Ibrexafungerp demonstrates broad in vitro activity against various Candida spp. including C. auris and C. auris isolates with fks mutations. Minimum inhibitory concentration (MIC50 and MIC90) values in >400 C. auris isolates were 0.5 µg/mL and 1.0 µg/mL, respectively. Clinical results were reported for two patients with invasive candidiasis or candidemia due to C. auris treated during the CARES (Candidiasis Caused by Candida Auris) trial, an ongoing open-label study. These patients experienced a complete response after treatment with ibrexafungerp. Thus, ibrexafungerp represents a promising new antifungal agent for treating C. auris infections.

KW - Antifungal

KW - Candida auris

KW - Ibrexafungerp

KW - Resistance

U2 - 10.3390/antibiotics9090539

DO - 10.3390/antibiotics9090539

M3 - Review

C2 - 32854252

AN - SCOPUS:85089840686

VL - 9

SP - 1

EP - 13

JO - Antibiotics

JF - Antibiotics

SN - 2079-6382

IS - 9

M1 - 539

ER -

ID: 250550673